An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patients lacking suitable alternative treatment options.

This is an open-label, single-arm, Phase IIb study to evaluate the efficacy, safety, tolerability and PK profile of F901318 in participants with fungal infections lacking suitable alternative treatment options.